ABOUT US OUR PRODUCTS DISTRIBUTORS TECHNOLOGY INVESTORS NEWS CENTER Diaxonhit, the leading French provider of specialty in vitro diagnostic solution. Navigation ABOUT US OVERVIEW HISTORY EXECUTIVE COMMITTEE MANAGEMENT BOARD SUPERVISORY BOARD JOIN US CONTACTS Print CLICK HERE TO PRINT CLICK HERE TO DOWNLOAD AS PDF Send this article Home » About Us » Overview Overview The Diaxonhit group is a French fully integrated leader in the field of in-vitro diagnostic with expertise ranging from discovery to commercialization of specialty diagnostic products. As a result of the acquisition of InGen BioSciences by Exonhit, the new Diaxonhit group benefits from the complementary capabilities derived from both companies’ business models. Its growth is based on the continued development of its distribution activities, and the development of its high added value proprietary innovative diagnostic products. Diaxonhit owns a broadened and diversified portfolio of proprietary diagnostic products in three specialty areas : transplantation, infectious diseases and cancer diagnosis. The group is currently marketing two proprietary products, TQS® (Tetanus Quick Stick) for the evaluation of patients’ immune status against tetanus, and BJI Inoplex for the diagnosis of bone joint prosthetic infections. The group also commercializes AlloMap, a molecular test for the surveillance of heart-transplant patients, under an exclusive licence for Europe. Additionally, Diaxonhit develops other diagnostic products using its molecular biology platform, including Dx15, a molecular diagnostic test for thyroid cancer. Diaxonhit’s commercial affiliate, InGen, is currently the leading independent distributor of in vitro diagnostics in the French market. It markets specialtydiagnostic tests to public and private clinical laboratories. InGen is the market leader in France for distribution of HLA’s tests (Human Leukocyte Antigen) that assess the compatibility between donors and recipients for organ and bone marrow transplants, and enable surveillance of rejection after transplantation. InGen also distributes tests for European and American partners in the field of infectious diseases, auto-immunity and quality control products. It sells, either directly or through reagent rental contracts, provides technical support and services a large base of diagnostic automates, in particular equipment developed by Luminex and installed in public and private clinical laboratories. Headquartered in Paris with its affiliate InGen based in Chilly-Mazarin (Paris suburbs), Diaxonhit has US offices in Rockville, Maryland. Diaxonhit employs approximately 85 associates, among which 20 are scientists. The Company has been listed on Alternext Euronext Paris since 2005 and is part of the Alternext BPI Innovation, PEA-PME 150 and Next Biotech indices (Reuters : ALEHT.PA - Bloomberg : ALEHT:FP). Site map - © 2016 Diaxonhit. All Rights Reserved - Legal information -